guly
Forumer storico
faremo la triste fine di vicurhonopata per quattro spiccioli....
vedo con piacere che finalmente hai capito la storia caro DilkSTAM
Pharma e Biotech - Europa NicOx : Quelli che aspettano ,,,, ridendo !!!
- Creatore Discussione acqua+
- Data di Inizio
- Stato
vedo con piacere che finalmente hai capito la storia caro DilkSTAM
guly
Forumer storico
faremo la triste fine di vicurhon :d opata per quattro spiccioli....
io li c'ero.e ci saro'anche con nicox,solo che non so con quante.ancora e' da decidere,il tempo c'e'.
doctor NO
NO nel DNA
Conférence Nicox - Pfizer !!
Auj. à 11:34
Ce matin aux US (heure locale):
Determination of Exogenous Nitric Oxide Using Stable Labeled Nitrogen Coupled with Liquid Chromatography-Mass Spectrometry
Tracks: Contributed Papers: Analytical Methodology / Hyphenated Methods - Small Molecule (e.g., GC-MC, LC-MS, Etc) / Biological Matrix
Date/Time: Tuesday, November 10, 2009
8:00 AM - 12:00 PM
Location: T2047
Description:
Nitric oxide (NO) is involved in many signals of the human body and can influence processes such as vasodilation and inflammation. There is potential to regulate these processes using exogenous NO therapy. NO can be quantified indirectly via oxidative metabolites, nitrite and nitrate, using fluorometric (2,3-diaminonapththalene [DAN] reaction) and colorimetric (Griess reaction) analysis. While useful, these methods cannot distinguish between endogenous levels of NO and levels generated from exogenous therapy. Here we describe the use of stable-labeled [15N]NO-donating moiety coupled with the mass selectivity of LC-MS/MS to quantify exogenous NO in biological samples. [15N]Nitrite was derivatized with DAN using literature methods to form [15N]-naphthotriazole (NAT). Conversion of nitrate to nitrite was achieved using nitrate reductase. LC-MS/MS methods were developed to quantify concentrations of [14N]NAT and [15N]NAT. Time course incubations were performed using rat liver S9 with a [15N]NO-donating substrate, and NO release was monitored. Levels of [15N]nitrite were calculated based on natural abundance of nitrogen isotopes. The mass unit selectivity of the LC-MS/MS method allows for separation between [14N]NAT and [15N]NAT. This improved sensitivity significantly reduced background contribution of endogenous NO. Low nanomolar changes in NO levels can be detected over conventional fluorometric and colorimetric methods. The efficiency of nitrate conversion and derivatization was assessed against a [15N]NAT standard, and efficiency was found to be greater than 80%. Following incubation of a [15N]NO-donating substrate in rat liver S9, an increase in NO formation over time was demonstrated. A sensitive, selective LC/MS/MS method was developed to quantify exogenous NO levels in biological samples resulting from NO-donating therapeutics. The selectivity of this stable-label-LC/MS/MS method offers a marked advantage over traditional colorimetric methods with respect to elucidation of NO levels resulting from exogenous sources.
Speakers:
Author
Miss Minerva R. Batugo
Scientist, Pfizer Global Research & Development
Author
Stefano Biondi
NicOx Research Institute
Author
Claudio De Nardi
NicOx Research Institute
Author
Francesco Impagnatiello
NicOx Research Institute
Author
Dr. Theodore R. Johnson
Senior Principal Scientist, Pfizer Global Research & Development
Auj. à 11:34
Ce matin aux US (heure locale):
Determination of Exogenous Nitric Oxide Using Stable Labeled Nitrogen Coupled with Liquid Chromatography-Mass Spectrometry
Tracks: Contributed Papers: Analytical Methodology / Hyphenated Methods - Small Molecule (e.g., GC-MC, LC-MS, Etc) / Biological Matrix
Date/Time: Tuesday, November 10, 2009
8:00 AM - 12:00 PM
Location: T2047
Description:
Nitric oxide (NO) is involved in many signals of the human body and can influence processes such as vasodilation and inflammation. There is potential to regulate these processes using exogenous NO therapy. NO can be quantified indirectly via oxidative metabolites, nitrite and nitrate, using fluorometric (2,3-diaminonapththalene [DAN] reaction) and colorimetric (Griess reaction) analysis. While useful, these methods cannot distinguish between endogenous levels of NO and levels generated from exogenous therapy. Here we describe the use of stable-labeled [15N]NO-donating moiety coupled with the mass selectivity of LC-MS/MS to quantify exogenous NO in biological samples. [15N]Nitrite was derivatized with DAN using literature methods to form [15N]-naphthotriazole (NAT). Conversion of nitrate to nitrite was achieved using nitrate reductase. LC-MS/MS methods were developed to quantify concentrations of [14N]NAT and [15N]NAT. Time course incubations were performed using rat liver S9 with a [15N]NO-donating substrate, and NO release was monitored. Levels of [15N]nitrite were calculated based on natural abundance of nitrogen isotopes. The mass unit selectivity of the LC-MS/MS method allows for separation between [14N]NAT and [15N]NAT. This improved sensitivity significantly reduced background contribution of endogenous NO. Low nanomolar changes in NO levels can be detected over conventional fluorometric and colorimetric methods. The efficiency of nitrate conversion and derivatization was assessed against a [15N]NAT standard, and efficiency was found to be greater than 80%. Following incubation of a [15N]NO-donating substrate in rat liver S9, an increase in NO formation over time was demonstrated. A sensitive, selective LC/MS/MS method was developed to quantify exogenous NO levels in biological samples resulting from NO-donating therapeutics. The selectivity of this stable-label-LC/MS/MS method offers a marked advantage over traditional colorimetric methods with respect to elucidation of NO levels resulting from exogenous sources.
Speakers:
Author
Miss Minerva R. Batugo
Scientist, Pfizer Global Research & Development
Author
Stefano Biondi
NicOx Research Institute
Author
Claudio De Nardi
NicOx Research Institute
Author
Francesco Impagnatiello
NicOx Research Institute
Author
Dr. Theodore R. Johnson
Senior Principal Scientist, Pfizer Global Research & Development
doctor NO
NO nel DNA
November 09, 2009 12:01 PM Eastern Time 
Pfizer Announces Global Research Network
Five Main Research Centers Will Drive Scientific Innovation
NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth. This global network brings together scientific strengths from both companies, continues efforts to increase research productivity, focuses disease-area research in single locations and more efficiently uses the company’s real estate.
Pfizer will have five main research sites that will serve as central hubs for research activities in BioTherapeutics, PharmaTherapeutics and Vaccines. These sites are: Cambridge, Mass.; Groton, Conn.; Pearl River, N.Y.; La Jolla, Calif.; and Sandwich, U.K. These research-oriented laboratories will be supplemented by specialized research capabilities, such as monoclonal antibody discovery in San Francisco, regenerative medicine work in Cambridge, U.K., and research and development activities in Shanghai, China.
“By focusing our R&D operations in these centers, we are building the world’s premier biopharmaceutical R&D enterprise,” said Mikael Dolsten, president of BioTherapeutics Research & Development. “This new structure puts Pfizer in the best position to conduct cutting-edge research within and beyond our own laboratories and to deliver a portfolio of high-impact medicines to patients.”
As part of the consolidation of research sites, Pfizer will significantly reduce R&D activities at some of its sites. The company will move a number of functions from Collegeville, Pa.; Pearl River, N.Y.; and St. Louis to other locations and will discontinue R&D operations in Princeton, N.J.; Chazy, Rouses Point and Plattsburgh, N.Y.; Sanford and Research Triangle Park, N.C.; and Gosport, Slough/Taplow, U.K. In addition, Pfizer will consolidate R&D functions from its New London, Conn., site to its nearby research facility in Groton, Conn.
As a result of these changes, Pfizer will reduce its global R&D square footage by 35 percent. R&D activities will now be conducted at five main sites and nine specialized units around the world as compared with 20 R&D sites upon closing the acquisition of Wyeth on October 16, 2009.
“In less than a month, we have made complex business decisions needed to combine these two R&D organizations thoughtfully yet quickly,” said Martin Mackay, president, PharmaTherapeutics Research & Development. “Moving forward on our aggressive timeline, we are analyzing the combined portfolio and prioritizing research projects that will address unmet medical need and bring Pfizer’s scientific and competitive advantage to the benefit of patients.”
While these changes are expected to bolster productivity and reduce costs, they will result in staff
anche pfizer post fusione stessa strategia che merck
Pfizer Announces Global Research Network
Five Main Research Centers Will Drive Scientific Innovation
NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth. This global network brings together scientific strengths from both companies, continues efforts to increase research productivity, focuses disease-area research in single locations and more efficiently uses the company’s real estate.
Pfizer will have five main research sites that will serve as central hubs for research activities in BioTherapeutics, PharmaTherapeutics and Vaccines. These sites are: Cambridge, Mass.; Groton, Conn.; Pearl River, N.Y.; La Jolla, Calif.; and Sandwich, U.K. These research-oriented laboratories will be supplemented by specialized research capabilities, such as monoclonal antibody discovery in San Francisco, regenerative medicine work in Cambridge, U.K., and research and development activities in Shanghai, China.
“By focusing our R&D operations in these centers, we are building the world’s premier biopharmaceutical R&D enterprise,” said Mikael Dolsten, president of BioTherapeutics Research & Development. “This new structure puts Pfizer in the best position to conduct cutting-edge research within and beyond our own laboratories and to deliver a portfolio of high-impact medicines to patients.”
As part of the consolidation of research sites, Pfizer will significantly reduce R&D activities at some of its sites. The company will move a number of functions from Collegeville, Pa.; Pearl River, N.Y.; and St. Louis to other locations and will discontinue R&D operations in Princeton, N.J.; Chazy, Rouses Point and Plattsburgh, N.Y.; Sanford and Research Triangle Park, N.C.; and Gosport, Slough/Taplow, U.K. In addition, Pfizer will consolidate R&D functions from its New London, Conn., site to its nearby research facility in Groton, Conn.
As a result of these changes, Pfizer will reduce its global R&D square footage by 35 percent. R&D activities will now be conducted at five main sites and nine specialized units around the world as compared with 20 R&D sites upon closing the acquisition of Wyeth on October 16, 2009.
“In less than a month, we have made complex business decisions needed to combine these two R&D organizations thoughtfully yet quickly,” said Martin Mackay, president, PharmaTherapeutics Research & Development. “Moving forward on our aggressive timeline, we are analyzing the combined portfolio and prioritizing research projects that will address unmet medical need and bring Pfizer’s scientific and competitive advantage to the benefit of patients.”
While these changes are expected to bolster productivity and reduce costs, they will result in staff
anche pfizer post fusione stessa strategia che merck
Netzach
Forumer storico
viralic
Forumer storico
,... Solo noi zeru strategia
Caro Dickstrugumdranghetesim,
ti vedo ultimamente molto negativo.....è una impostazione satirica la tua, o una prima presa di distanza dall trio medusa.........o ex trio ???
acqua+
ONDA NITRICA
faremo la triste fine di vicurhon
Unità di misura : 1 spicciolo = 25 eurelli
ho fatto un patto d'onore nitrico.... :Y :Y 
... Con docno e acqua plusssssssss ... Un agreement tra gentiluomini...- Stato
